---
title: "Eliquis (apixaban) in nonvalvular atrial fibrillation: Drug interactions questions"
description: "Drug interactions questions on Eliquis (apixaban) in nonvalvular atrial fibrillation, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Which drug interactions require an Eliquis dose reduction in atrial fibrillation? Can Eliquis be taken with rifampin, carbamazepine, phenytoin, or St. John’s wort? Can Eliquis be taken with aspirin, clopidogrel, or NSAIDs? 3 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/drug-interactions"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Eliquis (apixaban) in nonvalvular atrial fibrillation: Drug interactions questions

Manufacturer: Bristol-Myers Squibb Company; Pfizer Inc  
Prescribing information: [Eliquis](https://packageinserts.bms.com/pi/pi_eliquis.pdf)

## Drug interactions

<a id="eliquis-cyp3a4-pgp-inhibitors"></a>

### Which drug interactions require an Eliquis dose reduction in atrial fibrillation?

> “Combined P-gp and Strong CYP3A4 Inhibitors: Inhibitors of P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) increase exposure to apixaban and increase the risk of bleeding. For patients receiving ELIQUIS doses of 5 mg or 10 mg twice daily, reduce the dose of ELIQUIS by 50% when ELIQUIS is coadministered with drugs that are combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or ritonavir). In patients already taking 2.5 mg twice daily, avoid coadministration of ELIQUIS with combined P-gp and strong CYP3A4 inhibitors. Clarithromycin Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor, pharmacokinetic data suggest that no dose adjustment is necessary with concomitant administration with ELIQUIS.”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=Combined%20P%2Dgp%20and%20Strong%20CYP3A4%20Inhibitors%3A,with%20concomitant%20administration%20with%20ELIQUIS.)

> “For diltiazem, no dose adjustment of ELIQUIS is required”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=For%20diltiazem%2C%20no%20dose%20adjustment%20of%20ELIQUIS%20is)

Note: 10 mg twice daily is the initial dose for treatment of DVT and PE; the NVAF doses are 5 mg and 2.5 mg twice daily.

<a id="eliquis-cyp3a4-pgp-inducers"></a>

### Can Eliquis be taken with rifampin, carbamazepine, phenytoin, or St. John’s wort?

> “Combined P-gp and Strong CYP3A4 Inducers: Avoid concomitant use of ELIQUIS with combined P-gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease exposure to apixaban.”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=Combined%20P%2Dgp%20and%20Strong%20CYP3A4%20Inducers%3A,will%20decrease%20exposure%20to%20apixaban.)

> “Apixaban is a substrate of both CYP3A4 and P-gp. Concomitant use with drugs that are 
> combined P-gp and strong CYP3A4 inducers decreases exposure to apixaban [see Clinical 
> Pharmacology (12.3)] which increases the risk for stroke and other thromboembolic events.”

Source: [ELIQUIS: Prescribing information, page 7, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=7)

<a id="eliquis-aspirin-antiplatelets"></a>

### Can Eliquis be taken with aspirin, clopidogrel, or NSAIDs?

> “Anticoagulants and Antiplatelet Agents: Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk post-acute coronary syndrome patients treated with aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=Anticoagulants%20and%20Antiplatelet%20Agents%3A%20Coadministration,with%20apixaban%20compared%20to%20placebo.)

> “In ARISTOTLE, concomitant use of aspirin increased the bleeding risk on ELIQUIS from 1.8% per 
> year to 3.4% per year and concomitant use of aspirin and warfarin increased the bleeding risk 
> from 2.7% per year to 4.6% per year. In this clinical trial, there was limited (2.3%) use of dual 
> antiplatelet therapy with ELIQUIS.”

Source: [ELIQUIS: Prescribing information, page 7, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=7)

## Related pages
- [Medical information: Eliquis (apixaban): Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation)
- [Indication](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/safety)
- [Specific populations](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/access-and-coverage)
